# US 2022/0031804 A1 · Therapeutic agent of uremia containing alarin as the main ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031804 A1
- Document ID: US20220031804A1
- Status: Published application
- Kind: A1
- Application number: 17/400,629
- Filed: 2021-08-12
- Published: 2022-02-03
- Earliest claimed: 2017-12-26
- Assignees: Ju Tide Co., Ltd.
- Applicants: Ju Tide Co., Ltd.
- Inventors: Jong-Chul KIM
- Web page: https://patentgrep.com/patent/US20220031804A1

## CPC

- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 38/1709: {from mammals}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Provided is a novel use of alarin derived from a splice variant of galanin-like peptide (GALP) RNA and thus having an amino acid sequence similar to that of galanin, with a therapeutic agent of uremia, and the therapeutic agents of uremia according to the presently claimed subject matter include alarin as the main ingredient.

## Claims

### Claim at position 1

-6. (canceled)

### Claim 7

A method of treating uremia comprising administering to a subject in need thereof a pharmaceutical composition comprising alarin as an active ingredient, wherein the alarin is a human-derived alarin trifluoroacetate salt having the amino acid sequence: H-Ala-Pro-Ala-His-Arg-Ser-Ser-Thr-Phe-Pro-Lys-Trp-Val-Thr-Lys-Thr-Glu-Arg-Gly-Arg-Gln-Pro-Leu-Arg-Ser-OH-trifluoroacetate salt (SEQ ID NO: 1).

### Claim 8 (depends on 7)

The method of claim 7, wherein the alarin has a molecular weight of 2894.29 and a molecular formula of C127H206N43O38.

### Claim 9 (depends on 7)

The method of claim 7, wherein the alanine is administered in an amount of 0.5 mg to 10 mg per 60 kg adult body weight.

### Claim 10 (depends on 7)

The method of claim 7, wherein the composition is administered by injection.

### Claim 11 (depends on 10)

The method of claim 10, wherein the injection is subcutaneous muscle injection.
